Delanoy et al. reviewed 948 patients from three French pharmacovigilance databases and identified thirty-five with hematologic irAEs probably or certainly related to anti-PD-1 or anti-PD-L1 immunotherapy; the most commonly identified were neutropenia, autoimmune hemolytic anemia, and immune thrombocytopenia in nine patients (26%) each [45]. This evidence concerns the gene CD274 and autoimmune hemolytic anemia.